Filtered By:
Infectious Disease: Coronavirus
Vaccination: Vaccines
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 194 results found since Jan 2013.
Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
AbstractReports of cerebral venous sinus thrombosis and intracranial hemorrhage (ICH) following the administration of coronavirus vaccines have raised concerns regarding their safety. Although no regulatory authority has recognized ICH as an adverse event associated with tozinameran (BNT162b2, Pfizer-BioNTech), fatal and non-fatal cases have been reported. In Japan, 10 fatal cases (five men and women) have been reported to date. Four of the five women died of ICH and the other died of aspiration pneumonia, whereas all five men died of causes other than stroke. This imbalance is incompatible with the mortality data on cardi...
Source: Journal of Pharmaceutical Policy and Practice - May 31, 2021 Category: Pharmaceuticals Source Type: research
Unexplained arterial thrombosis: approach to diagnosis and treatment
We present a structured approach to diagnosis with consideration of common causes, including atherosclerosis and embolism, as well as uncommon causes, including medications and substances, vascular and anatomic abnormalities, systemic disorders, and thrombophilias. We highlight areas of management that have evolved within the past 5 years, including the use of dual-pathway inhibition in atherosclerotic disease, antithrombotic therapy selection in embolic stroke of undetermined source and left ventricular thrombus, the role of closure of patent foramen ovale for secondary stroke prevention, and the thrombotic potential of c...
Source: Atherosclerosis - December 10, 2021 Category: Cardiology Authors: Jori E May Stephan Moll Source Type: research
Carotid free-floating thrombus during COVID-19 vaccine era: causality or not?
AbstractCarotid free-floating thrombus (FFT) is very rarely diagnosed in patients with acute ischemic stroke. It is a real clinical emergency due to the significant risk of death associated with thromboembolic complications. Herein, we present three patients with ischemic stroke caused by carotid FFT after less than 20 days from administration of mRNA vaccine BNT162b1 (Pfizer/BioNTech) for Severe Acute Respiratory Syndrome—CoronaVirus 2 (SARS-CoV-2). To our knowledge, these are the first cases reporting carotid FTT following SARS-CoV-2 vaccination.
Source: Neurological Sciences - August 3, 2022 Category: Neurology Source Type: research
Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe
Background
As mortality from coronavirus disease 2019 (COVID-19) is strongly age-dependent, we aimed to identify population subgroups at an elevated risk for adverse outcomes from COVID-19 using age-/gender-adjusted data from European cohort studies with the aim to identify populations that could potentially benefit from booster vaccinations.
Methods
We performed a systematic literature review and meta-analysis to investigate the role of underlying medical conditions as prognostic factors for adverse outcomes due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including death, hospitalisation, intensive c...
Source: European Respiratory Review - November 2, 2022 Category: Respiratory Medicine Authors: Vardavas, C. I., Mathioudakis, A. G., Nikitara, K., Stamatelopoulos, K., Georgiopoulos, G., Phalkey, R., Leonardi-Bee, J., Fernandez, E., Carnicer-Pont, D., Vestbo, J., Semenza, J. C., Deogan, C., Suk, J. E., Kramarz, P., Lamb, F., Penttinen, P. Tags: Respiratory infections and tuberculosis Reviews Source Type: research
FDA Experts Vote to Make All COVID-19 Vaccines and Boosters Bivalent
In a unanimous decision, all 21 voting members of the U.S. Food and Drug Administration’s (FDA) vaccine committee recommended that the U.S. start using the same COVID-19 virus strain in all of the COVID-19 vaccines, including primary and booster doses.
That means the bivalent booster dose, which targets both the original SARS-CoV-2 strain and the Omicron BA.4/5 strains, would soon become the only type used for all primary shots and boosters.
The decision reflects a turning point in the pandemic. Until now, vaccine makers have tried to keep up with constantly evolving variants, but they’ve always been a few step...
Source: TIME: Health - January 27, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature
Ther Adv Drug Saf. 2023 May 21;14:20420986231165674. doi: 10.1177/20420986231165674. eCollection 2023.ABSTRACTAmid the coronavirus disease 2019 (COVID-19) pandemic, massive immunization campaigns became the most promising public health measure. During clinical trials, certain neurological adverse effects following immunization (AEFIs) were observed; however, acceptable safety profiles lead to emergency authorization for the distribution and use of the vaccines. To contribute to pharmacovigilance and lessen the potential negative impact that vaccine hesitancy would have on immunization programs, we conducted a review of the...
Source: Adv Data - May 24, 2023 Category: Epidemiology Authors: Sara Eslait-Olaciregui Kevin Llin ás-Caballero David Pati ño-Manjarrés Thomas Urbina-Ariza Juan Fernando Cediel-Becerra Camilo Alberto Dom ínguez-Domínguez Source Type: research
Preparations for the upcoming pilgrimage: heat exhaustion and respiratory diseases are the priority
Over 2 million Muslim pilgrims are expected to participate in this year’s hajj that begins next week in Saudi Arabia’s holy city of Mecca.
In preparation, the Saudi Ministry of Health with support from World Health Organization (WHO) has put in place measures to prevent and rapidly address any health issues that could arise during the hajj, including the Middle East respiratory syndrome coronavirus (MERS-CoV) and other respiratory diseases.
In addition, WHO has contributed to the training of more than 25 health cadres from the cities of Jeddah, Mecca and Madinah on rapid response to health emergencies. The training f...
Source: WHO EMRO News - September 6, 2016 Category: Middle East Health Source Type: news
Preparations for the upcoming pilgrimage: heat exhaustion and respiratory diseases are a priority
Over 2 million Muslim pilgrims are expected to participate in this year’s hajj that begins next week in Saudi Arabia’s holy city of Mecca.
In preparation, the Saudi Ministry of Health with support from World Health Organization (WHO) has put in place measures to prevent and rapidly address any health issues that could arise during the hajj, including the Middle East respiratory syndrome coronavirus (MERS-CoV) and other respiratory diseases.
In addition, WHO has contributed to the training of more than 25 health cadres from the cities of Jeddah, Mecca and Madinah on rapid response to health emergencies. The training f...
Source: WHO EMRO News - September 6, 2016 Category: Middle East Health Source Type: news
Superbugs, Anti-Vaxxers Make WHO ’ s List Of 10 Global Health Threats
(CNN) — From climate change to superbugs, the World Health Organization has laid out 10 big threats to our global health in 2019.
And unless these threats get addressed, millions of lives will be in jeopardy.
Here’s a snapshot of 10 urgent health issues, according to the United Nations’ public health agency:
Not vaccinating when you can
One of the most controversial recent health topics in the US is now an international concern.
“Vaccine hesitancy — the reluctance or refusal to vaccinate despite the availability of vaccines — threatens to reverse progress made in tackling vaccine-prevent...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 21, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Local TV Source Type: news
Top White House Official Joins Baker In Boston For Beth Israel Tour
BOSTON (CBS) – A top White House official was in Boston Friday to get a closer look at the coronavirus response in Massachusetts. Health and Human Services Secretary Alex Azar visited the Beth Israel Deaconess Medical Center with Governor Charlie Baker to tour the hospital’s COVID-19 test kit assembly areas and learn more about the research there.
“There is no better place in this country to come learn about what’s going on with respect to COVID, with respect to treatments, with respect to testing, with respective vaccines, with respect to care, than right here and we really appreciate your being with us today,...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 12, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Events Health Healthcare Status Politics Syndicated Local Alex Azar Beth Israel Deacones Medical Center Charlie Baker Coronavirus Source Type: news
We Need a COVID-19 Vaccine. We Also Need Transparency About Its Development
The authorization of an effective vaccine will mark perhaps the biggest turning point in the battle against coronavirus, but only if enough people are willing to get vaccinated. There have been substantial declines in public willingness to get vaccinated against COVID-19, despite immense, unprecedented public investments in vaccine development. In one survey, barely half of Americans said they would get the vaccine as soon as it was available, numbers that will undermine the benefits of even a highly effective vaccine.
It is no mystery why trust in a potential vaccine has plummeted. Operation Warp Speed, the Trump Administ...
Source: TIME: Health - September 18, 2020 Category: Consumer Health News Authors: Dr. Ashish K. Jha Tags: Uncategorized COVID-19 Source Type: news
Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients.
CONCLUSION: Dipyridamole may substantially help improve the clinical outcomes of COVID-19 treatment. The pharmacokinetics profile of the drug is well established which makes it easier to design an appropriate therapeutic course. The drug is also generally safe, affordable, and available worldwide. Initial clinical trials have shown a substantial promise for dipyridamole in treating critically ill COVID-19 patients, yet larger randomized and controlled trials are needed to confirm this promise.
PMID: 33001004 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - September 30, 2020 Category: Drugs & Pharmacology Authors: Aliter KF, Al-Horani RA Tags: Curr Pharm Des Source Type: research
Johnson & Johnson, AstraZeneca coronavirus vaccine trials set to resume
Investigators found a participant’s illness, a stroke, did not appear to be related to the vaccine.
Source: Washington Post: To Your Health - October 23, 2020 Category: Consumer Health News Authors: Carolyn Y. Johnson Source Type: news
